Jordan Scott, MD
Allergy & Immunology · Leominster, MANPI 1275517245
Payments from drug & device makers
Across 650 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$2K
- CSL Behring$854
- Takeda Pharmaceuticals U.S.A., Inc.$695
- AbbVie$650
- plus $4K from 33 others
What the payments were for
- Consulting fees$160%
- Food & beverage$12,53298%
- Education$2902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 111 | $2,971 |
| Regeneron Healthcare Solutions, Inc. | 115 | $1,615 |
| GSK | 103 | $1,587 |
| CSL Behring | 36 | $854 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $695 |
| AbbVie | 27 | $650 |
| Pfizer | 34 | $601 |
| Novartis | 24 | $538 |
| Pharming Healthcare, Inc. | 23 | $533 |
| Sanofi | 25 | $505 |
| Blueprint Medicines Corporation | 15 | $345 |
| Kaleo, Inc. | 10 | $221 |
| Amgen(2 entities) | 9 | $197 |
| Biocryst US Sales Co., LLC | 7 | $187 |
| Genentech USA, Inc. | 8 | $152 |
| Aimmune Therapeutics, Inc. | 6 | $117 |
| GC Biopharma USA, Inc. | 4 | $106 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Lilly USA, LLC | 3 | $81 |
| Invivyd Inc | 3 | $79 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $79 |
| Grifols USA, LLC | 3 | $77 |
| Alk-abello, Inc | 4 | $69 |
| LEO Pharma Inc. | 3 | $58 |
| Bio Products Laboratory USA, Inc. | 4 | $50 |
| Mylan Specialty L.p. | 2 | $45 |
| Kedrion Biopharma, Inc. | 2 | $40 |
| Boehringer Ingelheim | 3 | $39 |
| Optinose US, Inc. | 2 | $37 |
| Circassia Inc. | 2 | $32 |
| Cycle Pharmaceuticals Inc | 1 | $31 |
| Galderma Laboratories, L.p. | 2 | $28 |
| Shire North American Group Inc | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Covis Pharma GmbH | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $16 |
| ADMA Biomanufacturing LLC | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,838 in reported general payments places this provider in the 60th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 91 | $430,637 |
| Dupixent PenDupilumab | 76 | $292,513 |
| Dupixent SyringeDupilumab | 70 | $268,604 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $154,595 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $129,926 |
| NucalaMepolizumab | 11 | $112,495 |
| HyqviaIgg/Hyaluronidase,recombinant | 24 | $104,824 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $37,355 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $34,631 |
| Epinephrine | 210 | $32,076 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $18,597 |
| Cromolyn Sodium | 32 | $10,969 |
| Spiriva RespimatTiotropium Bromide | 17 | $10,656 |
| DuleraMometasone/Formoterol | 26 | $9,983 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Gammagard Liquid, Hyqvia | $695 | $389,34571 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,587 | $191,413149 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,971 | $23,56645 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $39 | $18,12732 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $31 | $10,96932 claims |
| Alk-abello, IncOdactra | $69 | $4,39613 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $90 | $4,37017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Leominster
- Francisco BonillaLeominster$188K
- David RiesterLeominster$13K
- S David MillerNorth Dartmouth$8.7M
- Wanda PhipatanakulBoston$3.2M
- Maria CastellsGardner$2.8M
- Rima RachidBoston$1.1M
- Duane WesemannBoston$1M
- Matthew GiannettiBoston$720K
- John LeeBoston$695K
- Aleena BanerjiBoston$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.